CSL Limited: Influenza, Human trials

The registry lists 49 Influenza, Human studies with CSL Limited as lead sponsor. 0 are open to participants now and 31 have results posted.

Phase 1 7Phase 2 15Phase 3 20Phase 4 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of AgeCompletedNCT05501561Phase 2Results posted
• A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or UnprimedCompletedNCT05422326Phase 2Results posted
• A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of AgeCompletedNCT05044195Phase 3Results posted
• Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older AdultsCompletedNCT04782323Phase 2Results posted
• A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza VaccineCompletedNCT04669691Phase 2Results posted
• Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older AdultsCompletedNCT04576702Phase 2Results posted
• Safety and Immunogenicity Study of QIVc in Healthy Pediatric SubjectsCompletedNCT04074928Phase 3Results posted
• Efficacy Study With QIVc in Pediatric SubjectsCompletedNCT03932682Phase 3Results posted
• Phase 3 Safety and Immunogenicity Study of aQIV in Elderly AdultsCompletedNCT03314662Phase 3Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of AgeCompletedNCT03165617Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.CompletedNCT02914275Phase 3Results posted
• A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of AgeCompletedNCT02839330Phase 3Results posted
• Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of AgeCompletedNCT02587221Phase 3Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)CompletedNCT02583256Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of AgeCompletedNCT02545543Phase 3Results posted
• Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05CompletedNCT02255409Phase 3Results posted
• A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.CompletedNCT02214225Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 YearsCompletedNCT02212106Phase 4Results posted
• Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months OldCompletedNCT02035696Phase 1/2Results posted
• Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.CompletedNCT01964989Phase 3Results posted
• A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01863433Phase 4Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01857297Phase 4Results posted
• A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy VolunteersCompletedNCT01591837Phase 4Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric PopulationCompletedNCT00959049Phase 3Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in a Healthy Pediatric Population in the USACompletedNCT00958243Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Adults in the USACompletedNCT00958126Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy ChildrenCompletedNCT00940108Phase 2Results posted
• A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy AdultsCompletedNCT00938639Phase 2Results posted
• Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 YearsCompletedNCT00825162Phase 4Results posted
• A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus VaccineCompletedNCT00735475Phase 4Results posted
• A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy AdultsCompletedNCT00562484Phase 4Results posted
• A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of AgeCompletedNCT06087640Phase 3
• Safety, Reactogenicity, and Immunogenicity Study of a Self-Amplifying MRNA Influenza Vaccine in Healthy AdultsCompletedNCT06028347Phase 1
• The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and OlderCompletedNCT06015282Phase 3
• Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in AdultsCompletedNCT05875961Phase 1
• Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in AdultsCompletedNCT05874713Phase 2
• An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and OlderWithdrawnNCT04806529Phase 2/3
• Afluria Pregnancy RegistryCompletedNCT03442582
• Flucelvax (TIVc or QIVc) Pregnancy RegistryCompletedNCT03438487
• Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and AboveCompletedNCT02126761Phase 1
• Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza VaccineCompletedNCT02107807Phase 3
• Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical ConditionsCompletedNCT02091908Phase 3
• Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and OlderCompletedNCT00848848Phase 1
• Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)CompletedNCT00812019Phase 1
• A Study of the Safety, Tolerability & Immunogenicity of CSL Limited's Influenza Virus Vaccine In a Paediatric PopulationCompletedNCT00700193Phase 3
• Study of a Pandemic Influenza Vaccine in Elderly ParticipantsCompletedNCT00376402Phase 2
• Study of a Pandemic Influenza Vaccine in ChildrenCompletedNCT00370864Phase 2
• Phase II Study of Pandemic Influenza VaccineCompletedNCT00320346Phase 2
• Study of a Pandemic Influenza VaccineCompletedNCT00136331Phase 1